Peakdale Molecular was founded in 1992. Today, the Company’s customers include 18 of the top 20 global pharmaceutical companies and an increasing number of biotechnology companies. Its teams of chemists combine experience in pharmaceutical R&D and process development, medicinal chemistry, parallel synthesis and fine chemicals to deliver unique chemistry solutions to a range of drug discovery challenges. Application of less commonly used chemistry, including high temperature/pressure reactions, proprietary heterocyclic chemistry and nucleoside synthesis, enables Peakdale’s chemists to generate unique compounds for drug discovery. Peakdale operates in several distinct markets providing novel screening compounds, targeted screening libraries, catalogue intermediates, custom synthesis and contract research.
At Peakdale we offer a range of in vitro ADMET predictive models, delivering accurate and reproducible data, maintaining a focus on efficient turnaround times to facilitate our customers' drug discovery programs. In addition to our core assays, we also offer our clients the flexibility of bespoke assay design. The majority of our assays utilise sensitive "state of the art" triple quad LC-MS/MS ESI detection. Complementing our…
Peakdale has built up medicinal chemistry and computational chemistry expertise across therapeutic areas and spanning the drug discovery process from hit generation to Phase I clinical studies. Peakdale has a proven track record of success in producing robust candidates suitable for Proof-of-concept testing in vivo. To achieve this, the company utilises its highly experienced and committed teams to deliver on project goals and…
